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The role of the immune system in cancer has been studied extensively; immunity in the cancer microenvironment has a role in different 
phases of cancer development.1 Cancer cells usually 
express abnormal antigens which trigger the immune 
response to be activated against these cancerous cells.2 
Tumour-infiltrating lymphocytes (TIL), including cyto- 
toxic T-cells, are usually involved in tumour antigen 
recognition and anti-tumour immunity to destroy 
cancer cells during immune-surveillance.1,3 Normally, 
the initiation of the immune response by T-cells is 
mediated through T-cell receptor (TCR) recognition 
of the antigen and regulated by inhibitory and stimul- 
atory molecules expressed in these T-cells. The inhibitory 
molecules are considered as immune checkpoints for 
self-tolerance (i.e. protection from tissue damage during 
an immune response and prevention of developing 
autoimmune diseases). However, the inhibitory effect 
mediated by these immune checkpoint molecules may 
also be used as a mechanism for tumour cells to escape 
the immune response.4 One of these immune check- 
points is the programmed death receptor 1 (PD-1)/progr- 
ammed death ligand 1 (PD-L1) interaction [Figure 1].
PD-1 is a member of cluster of differentiation 
(CD)28 family that is expressed in T-cells.5 It is also 
expressed in B-cells, professional antigen presenting 
cells and natural killer cells.6 The PD-L1 was firstly 
identified by Dong et al. in 1999 and showed that 
there was an increase in the T-cell proliferation and 
interleukin (IL)-10 secretion by T-cells stimulated 
with PD-L1/B7-H1 and low levels of anti-CD3.7 In 
2000, Freeman et al. showed induction of PD-L1 
expression by cytokines as interferon (IFN)-γ or other 
inflammatory stimuli could result in attenuation of 
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abstract: Programmed death ligand 1 (PD-L1) is an inhibitory molecule expressed by cancer cells to supress 
T-cell activity and escape anti-tumour immunity. The role of PD-L1 in cancer has been studied extensively as 
it is considered an important immune checkpoint against immune over-activation through its interaction with 
Programmed death receptor 1 (PD-1) expressed on activated lymphocytes. PD-L1 expression was found to be 
enhanced by chemotherapy through different proliferation pathways. However, the predictive and prognostic value 
for PD-L1 expression in cancer patients treated with neoadjuvant chemotherapy (NAC) is not yet established. 
This review focused on the potential effects of chemotherapy on PD-L1 expression and the role of PD-L1 as a 
prognostic and predictive marker in NAC-treated cancer patients. In addition, the potential use of this marker in 
clinical practice is discussed.
Keywords: Programmed Cell Death 1 Ligand 1; Programmed Cell Death 1 Receptor; Neoadjuvant Therapy; Cancer.
امللخ�ص: ربيطة املوت املربمج-1 هو جزيء مثبط تعرب عنه اخلاليا ال�رسطانية لقمع ن�صاط اخلاليا الليمفاوية من النوع )ت( لالإفالت 
تعترب  لأنها  وا�صع  نطاق  على  ال�رسطان  يف  املربمج-1  املوت  ربيطة  دور  درا�صة  متت  ال�رسطانية.  الأورام  �صد  تن�صاأ  التي  املناعة  من 
تظهرعلى اخلاليا  التي  املربمج-1  املوت  م�صتقبل  تفاعلها مع  املناعي من خالل  للجهاز  املفرط  التن�صيط  مناعية هامة �صد  �صابطة 
الليمفاوية املن�صطة. ووجد اأن انت�صارربيطة املوت املربمج-1 تتعزز باملعاجلةالكيميائية من خالل م�صارات تكاثريةخمتلفة. ومع ذلك، 
فاإن القيمة التنبوؤية الإنذارية لظهورربيطة املوت املربمج-1 عند مر�صى ال�رسطان الذين يتلقومنعاجلة كيميائيةم�صبقة مل تتحدد بعد. 
هذه املراجعة تتناول تاأثري املعاجلة الكيميائية املحتمل على ظهور ربيطة املوت املربمج-1 واأهمية انت�صارها كعالمة تنبوؤية اإنذارية 
املوؤ�رس يف  ا�صتخدام هذا  اإمكانية  اإىل ذلك، متت مناق�صة  بالإ�صافة  امل�صبقة.  الكيميائية  يتلقون املعاجلة  الذين  ال�رسطان  لدى مر�صى 
املمار�صة ال�رسيرية.
الكلمات املفتاحية: جلني موت اخللية املربمج-1؛ م�صتقبالت موت اخللية املربجمة-1؛ العالج امل�صبق؛ ال�رسطان.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
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TCR/CD28–mediated T-cell activation which may be 
significant in the regulation of inflammatory or auto- 
immune reactions.8 PD-L1, also called B7-H1, is a 
member of B7 molecules which are involved in the 
regulation of T-cell response either through stimulation 
or inhibition.9 PD-L1 is generally widely expressed 
in different tissues from different lineages including 
lymphoid (i.e. immune cells) or non-lymphoid (i.e. 
epithelial and endothelial) lineages and in cancer cells 
that originate from these lineages.8,10 PD-L1 was found 
to inhibit proliferation of T-cells and production of 
cytokines such as IFN-γ and IL-2, through interaction 
with PD-1 expressed on these cells.11 In the cancer 
microenvironment, the interaction of PD-L1 which is 
expressed in cancer cells and PD-1 which is expressed 
in T-cells leads to the inhibition of cytotoxic T-cell activity, 
a decrease  in cytokines production by T-cells and ind- 
uction of T-regulatory cells. Therefore, this interaction 
protects tumour cells from destruction by cytotoxic 
T-cells and promotes tumour cell proliferation.1,2,12
Many studies chose to investigate the role of PD-
L1 expression in subjects not treated with neoadjuvant 
chemotherapy (NAC). For example, a study on triple 
negative breast cancer (TNBC) patients excluded patients 
treated with NAC.13 Similarly, several studies preferred 
to include patients who did not receive NAC.14–16 This 
exclusion was partly attributed to the possibility that 
chemotherapy may contribute to change the expression 
of specific markers; for example, the expression of 
progesterone receptor and cellular proliferation marker 
(Ki-67) in breast cancer was decreased after NAC.17
The effect of NAC on PD-L1 expression in cancer 
patients has not yet been established. Therefore, this 
review aimed to highlight the effect of chemotherapy 
on the expression of PD-L1, the potential use of PD-L1 
expressed in pre-treated patients as a predictive marker 
for the response to chemotherapy and whether it could 
be used as a prognostic disease marker.
post-neoadjuvant chemotherapy 
c h a n g e s i n  p r o g r a m m e d d e at h 
ligand 1 expression in different 
cancers 
Immunohistochemical detection of PD-L1 expression 
can be either increased or decreased by NAC according 
to the tumour type. It is known that chemotherapy 
provokes an immune response but, once PD-L1 is over- 
expressed, this immune response might be diminished. 
Increased expression of PD-L1 after NAC suggests that 
the immune response is inhibited which may contr- 
ibute to chemo-resistance and poor clinical outcome.18 
Therefore, a combination of chemotherapy and immun- 
otherapy was suggested to overcome this resistance. 
Conversely, decreased expression of PD-L1 may be 
associated with a better response to NAC treatment.
Cancers associated with increased Programmed 
Death Ligand 1 expression
Increased PD-L1 expression in association with NAC 
was demonstrated in post-treated specimens of ovarian, 
bladder and gastrointestinal cancers as well as head 
and neck squamous cell carcinoma (HNSCC).19–25 In 
epithelial ovarian cancer, 63% of PD-L1 negative tumours 
converted to positive PD-L1 tumours after NAC when 
patients received carboplatin and paclitaxel; the positivity 
rate in the PD-L1 positive samples increased from 
30% in pre-treated specimens to 53% in post-treated 
 
Figure 1: Depiction of the T-cell receptor recognition 
of the tumour antigen initiating the T-cell response 
which is regulated by inhibitory molecules expressed in 
T-cells such as programmed death receptor 1. However, 
tumour cells may use this inhibitory effect to escape the 
immune response.
PD-L1 = programmed death ligand 1; PD-1 = programmed death 
receptor 1.
 
Figure 2: Flowchart showing the different pathways 
involved in programmed death ligand 1 upregulation 
induced by chemotherapy treatment.
JAK/STAT = janus-activated kinase/signal transducers and activators 
of transcription; PI3K/Akt = phosphoinositide-3 kinase/protein kinase 
B; MAPK = mitogen-activated protein kinase; PD-L1 = programmed 
death ligand 1.
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specimens.19 This was further supported by findings 
showing that cisplatin treatment of ovarian cancer cell 
lines SKOV-3 and OVCAR-3 in vitro induced the 
expression of PD-L1.19 In addition, a high proportion of 
T-cells expressing PD-L1 were found in biopsies from 
ovarian high-grade serous carcinoma after NAC.20 
The expression of PD-L1 was increased in 76% of 
patients with urothelial carcinoma treated with cisplatin 
or carboplatin-based chemotherapy.21 Although the 
increased expression was not observed in post-treated 
oesophageal carcinoma specimens using immunohisto- 
chemistry, 5-fluorouracil induced surface expression 
of PD-L1 in oesophageal cancer (OE33) and colorectal 
cancer (HCT 116 p53+/+ and HCT 116 p53−/−) cell lines.22 
PD-L1 expression and TIL were increased after con- 
current chemoradiation therapy (CCRT) in rectal car- 
cinoma.23 Notably, sustained high expression of PD-
L1 in pre- and post-chemoradiotherapy specimens, 
associated with less increase in TIL, showed poorer 
overall survival (OS) and disease-free survival (DFS) 
compared to other patients.23
Inhibition of PD-L1 may be beneficial only in some 
ovarian cancer patients. PD-L1 is expressed significantly 
more in high grade tumours than in low grade tumours; 
therefore, a subgroup of advanced disease ovarian cancer 
patients with high grade tumours, expressing PD-L1, 
may benefit the most from therapy targeting PD-L1.19
In HNSCC, immunohistochemical analysis of 13 
negative cases of PD-L1 showed that nine cases (69.2%) 
showed increased PD-L1 expression after cisplatin 
treatment.25 Furthermore, patients who received neo- 
adjuvant cisplatin treatment showed more PD-L1 up-
regulation compared to patients who did not receive 
cisplatin.25 This was supported by findings showing 
increased PD-L1 expression in HNSCC cell lines 
(SNU-1066, SNU-1041, SNU-1076, Detroit-562, FaDu 
and PCI-13) treated with cisplatin alone.25
Cancers associated with decreased Programmed 
Death Ligand 1 expression 
Conversely, PD-L1 was downregulated in breast and 
squamous oral carcinoma, after treatment with NAC.26,27 
In the analysis of 58 breast specimens (56% of patients 
treated with doxorubicin and cyclophosphamide 
followed by taxane and the remaining patients received 
other agents), the positivity rate of PD-L1 expression 
decreased from 51% to 17.2% and 17 cases converted 
from positive to negative status in spite of the increase 
of T-cells.26 The comparison between NAC-treated and 
non-treated squamous oral carcinoma specimens showed 
that most of the treated specimens weakly expressed 
PD-L1, while non-treated specimens showed either strong 
or intermediate expression. Similarly, PD-1 expression 
was significantly less in NAC-treated specimens.27
Programmed Death Ligand 1 expression in lung 
cancer
In lung cancer, the expression of PD-L1 showed variable 
results regarding PD-L1 expression after NAC treatment. 
Sun et al. showed that PD-L1 expression significantly 
increased in platinum-based-treated specimens.28 PD-L1 
expression also increased in nine patients and decr- 
eased in two patients with lung squamous cell carcinoma 
after NAC; the positivity rate changed from 52.6% to 
61.8%.29 Expectedly, expression of PD-L1 was associated 
with worse DFS compared to the decreased expression. 
However, PD-L1 expression was not an independent 
predictor of DFS as determined by multiple regression 
analysis.30
Non-small cell lung cancer samples showed an 
overall decrease in PD-L1 expression after CCRT. The 
decreased PD-L1 expression was associated with better 
survival compared to samples with increased PD-L1 
expression (85.1 months versus 14.6 months).31 These 
findings were comparable to another study involving 
patients with non-small lung carcinoma treated with 
a pemetrexed-based regimen and paclitaxel-based 
chemotherapy.30 In this study, the positivity rate of PD-
L1 changed from 75% to 37.5% with effect on immune 
cell infiltration; decreased PD-L1 expression in tumour 
cells was associated with a better response to NAC. 
Remark et al.’s study found that PD-L1 expression in 
lung cancer was not changed by cisplatin-based NAC 
treatment indicating that NAC did not contribute to 
the modification of PD-L1 expression.32 Various results 
from different studies suggest that PD-L1 expression, in 
response to NAC treatment, may be cancer specific and 
that different NAC modalities may trigger distinct changes 
in PD-L1 expression involving different mechanisms.
proposed mechanisms of chemo- 
therapy-mediated-programmed 
death ligand 1 expression changes
Few studies have explored the mechanisms linked 
to PD-L1 expression changes associated with NAC. 
Chemotherapy may be involved in proliferative path- 
ways that can lead to enhanced PD-L1 expression in 
cancer [Figure 2].33
For instance, PD-L1 expression at the protein 
and mRNA levels was increased under the influence 
of 5-fluorouracil, gemcitabine and paclitaxel chemo- 
therapy in pancreatic cancer cell lines (MIA PaCa-
2, AsPC-1, Pan02).34 These three anti-cancer agents 
increased PD-L1 through Janus-activated kinase/signal 
transducers and activators of transcription signalling 
pathways and through phosphorylation by phospho- 
inositide-3 kinase/protein kinase B (PI3K/Akt) and 
mitogen-activated protein kinase (MAPK) pathways.34 
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In addition, HNSCC cancer cell lines (SNU-1066, 
SNU-1041, SNU-1076, Detroit-562, FaDu and PCI-
13) treated with cisplatin showed an increase in PD-
L1 expression along with up-regulation of extracellular 
signal-regulated kinase/MAPK. These pathways were 
found to contribute to chemoresistance. For example, 
activation of PI3K/Akt pathway was associated with 
chemotherapy resistance in urothelial carcinoma.35 
However, targeting the MAPK pathway enhanced the 
sensitivity of the tumour resistance to cisplatin and 
helped to overcome this resistance.36 
Inactivation of programmed cell death (i.e. 
apoptosis), is essential for cancer development. It was 
suggested that disabling apoptosis by anti-apoptotic 
factors may contribute to NAC resistance. For example, 
a gastric cancer cell line (SGC7901/5-FU) resistant 
to treatment with 5-fluorouracil was associated with 
overexpression of PD-L1 compared to a sensitive gastric 
cell line. A PD-L1 induced resistance was associated 
with up-regulation of anti-apoptotic proteins, including 
ATP binding cassette subfamily C member 1 and anti- 
apoptotic factor B-cell lymphoma 2, that may contr- 
ibute to the resistance. The blockage of PD-L1 by 
siRNA was found to overcome this resistance and 
inhibit proliferation.37
A novel mechanism of PD-L1 downregulation of 
expression by chemotherapy was discovered.38 Anth- 
racycline agents, including doxorubicin, were found 
to decrease the surface expression of PD-L1 in breast 
cancer cell lines (MDA-MB231 and SKBr3) in a dose 
and time-dependent manner. However, this effect was 
correlated with nuclear translocation of PD-L1 and 
increased nuclear phosphorylated Akt. PD-L1 was 
also found to have an anti-apoptotic function, in which 
its blockade by PD-L1 siRNA enhanced the effect of 
doxorubicin-induced apoptosis and which was PI3K/
Akt pathway dependent.38
programmed death ligand 1 as a 
potential predictive measure for 
the response to neoadjuvant chemo- 
therapy
PD-L1 expressed in pre-treated specimen has been 
investigated to identify patients who would be most 
likely to respond to NAC. Several studies have found 
that PD-L1 expression is associated with a pathological 
complete response (pCR) after NAC in breast cancer.39–42 
The analysis of 94 biopsies of breast cancer tissue 
revealed that pCR was associated with the epithelial 
and stromal expression of PD-L1. When patients were 
classified into groups, this association remained signif- 
icant in hormone-positive and Her2-postive breast 
cancer.39 Similarly, PD-L1 expression in tumour cells 
was associated with pCR in 54 biopsies of TNBC 
which remained significant in multivariate analysis. 
All patients with more than 25% expression of PD-
L1 and high TIL achieved pCR.40 Expression of PD-
L1 in tumour cells of Her2-positive breast cancer 
tumours showed a trend of association with pCR but 
did not reach significance.41 The evaluation of several 
predictive markers revealed that 20 out of 27 PD-L1-
positve invasive breast cancer cases showed excellent 
response to NAC using the Residual Cancer Burden 
score.41 The mechanisms underlying the differential 
response amongst different molecular types of breast 
carcinoma may be due to the differing biology of 
the three types i.e. the tumours may or may not be 
immunogenic.
Only Baras et al.’s study of bladder cancer found 
that PD-L1 was not associated with pCR.43 The 
expression of PD-L1 in invasive bladder carcinoma 
showed no significant difference between responders 
and resistant patients to cisplatin-based NAC.43
programmed death ligand 1 as a 
prognost ic marker in pat ients 
treated with neoadjuvant chemo- 
therapy
The role of PD-L1 as a prognostic marker in patients 
treated with NAC remains largely unknown. The 
results of several studies identifying the expression of 
PD-L1 in residual tumours (i.e. post-treated specimens) 
have been concordant. It has been reported that high 
PD-L1 expression in residual tumours was associated 
with poor clinical outcome in locally-advanced breast 
cancer after NAC. According to molecular subtypes, 
the association was more significant in the TNBC 
subtype.44 Patients with high PD-L1 expression and 
low CD8+ cells had a poor outcome compared to 
other groups.44 However, some studies found that 
PD-L1 expression in residual breast tumours was 
not associated with the clinical outcome.26,41 In post-
treated bladder cancer, disease-specific survival in 
PD-L1-positive patients was significantly lower than 
in PD-L1-negative patients.45 In lung cancer, both pre- 
and post-treated expression of PD-L1 was associated 
with worse OS; however, the association was signif- 
icant and independent in post-treated specimens 
indicating that PD-L1 status after NAC treatment is 
a better prognostic marker than PD-L1 status prior to 
NAC treatment.29 
Conclusion
Chemotherapy may cause an increase or decrease in 
the expression of PD-L1; this outcome seems to be 
cancer specific as shown by immunohistochemistry 
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analysis of pre- and post-treated specimens and cell 
line experiments. It is possible that PD-L1 is involved 
in chemoresistance through inhibiting the induction 
of T-cell activity pathways. Therefore, it may be 
important to consider combining immunotherapy 
and chemotherapy to improve the response to the 
treatment. Current evidence showed that increased 
PD-L1 expression in post-treated specimens is a poor 
prognostic marker; although, PD-L1 was shown to 
predict the response to NAC in breast cancer. Further 
studies are needed to validate this predictive role of 
PD-L1 in response to NAC in other cancers except 
breast cancer. Also, further broader investigations are 
required to explore the prognostic role of PD-L1.
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